Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2022, and raised the mid-point of 2022 total...

Related Keywords

France ,Germany ,Japan ,United States ,United Kingdom ,Italy ,Ireland ,Russia ,Dublin ,Spain ,Ukraine ,Erwinaze Erwinase ,Oxybate Xywav ,Asia Pacific ,Us Hart Scott Rodino ,Epidiolex Epidyolex ,Rob Iannone ,Bruce Cozadd ,Zymeworks Inc ,Roche Ltd ,Oncology Review Program ,Jazz Pharmaceuticals ,Drug Administration ,Gw Pharmaceuticals ,Nasdaq ,Exchange Commission ,Prnewswire Jazz Pharmaceuticals ,Corporate Development ,European Medicines Agency ,Company Quarterly Report On Form ,Dravet Syndrome ,Lennox Gastaut Syndrome ,Tuberous Sclerosis Complex ,Myoclonic Atonic Seizures ,Orphan Drug Exclusivity ,Idiopathic Hypersomnia ,Marketing Authorization Application ,Biologics Licensing Application ,Real Time Oncology Review Program ,Scott Rodino Antitrust Improvements Act ,Should Jazz ,Lower Limb Muscle ,Modified Ashworth Scale ,Fast Track Designation ,Own Equity ,Convertible Instruments ,Exchangeable Senior ,Effective Tax ,Dollar Term Loan ,Euro Term Loan ,Exchangeable Senior Notes ,Jazz Pharmaceutical ,Adjusted Consolidated ,Jazz Pharmaceutical Securities ,Quarterly Report ,Certain Line Items ,Net Debt ,Pro Forma ,Leverage Ratio ,Consolidated Adjusted ,